26 okt: USA: Væksten og privatforbruget overrasker positivt i tredje kvar..
26 okt: USA/økonomer: Fortsat optimisme i amerikansk økonomi trods handel..
26-10-2018 14:47:55

Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin

Bagsværd, Denmark, 26 October 2018 - Novo Nordisk today announced the headline results from PIONEER 8, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The 52-week trial investigated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared with placebo in 731 people with type 2 diabetes treated with insulin and an average duration of diabetes of 15 years. During the first 26-week treatment period, the total daily insulin dose was not allowed to be increased above baseline followed by a 26-week period where the insulin treatment was adjusted without restrictions.

Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 8 trial; a primary statistical approach[1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication.

When applying the primary statistical approach, the trial achieved its primary objective by demonstrating statistically significant and superior reductions in HbA1c and body weight with all three doses of oral semaglutide compared to placebo, all in addition to insulin, at week 26.

When applying the secondary statistical approach, from a mean baseline of 8.2%, people treated with 3, 7 and 14 mg oral semaglutide achieved reductions in HbA1c of 0.6%, 1.0% and 1.4% respectively, compared to no reduction (0.0%) in people treated with placebo, all in addition to insulin, at week 26, and 0.5%, 0.8% and 1.2% respectively, compared with 0.0% at week 52. The American Diabetes Association (ADA) treatment target of HbA1c below 7.0% was achieved by 36%, 47% and 64% of people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to 10% of people treated with placebo at week 52. In addition, from a mean baseline body weight of 85.9 kg, people treated with 3, 7 and 14 mg oral semaglutide experienced a weight loss of 1.0 kg, 2.9 kg and 4.3 kg, respectively, compared to a weight increase of 0.6 kg in people treated with placebo at week 52, all in addition to insulin. The mean total insulin dose at baseline was 60, 62 and 54 units/day for people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to 56 IU/day for people treated with placebo, and the total insulin dose at week 52 was increased by 2 units/day, reduced by 6 units/day and reduced by 7 units/day for people treated with 3, 7 and 14 mg oral semaglutide respectively, compared to an increase of 10 units/day for people treated with placebo.

In the 52-week trial, people treated with 3, 7 and 14 mg oral semaglutide experienced few and comparable levels of severe or blood glucose-confirmed hypoglycaemic episodes compared to placebo. Oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea, which diminished over time. In PIONEER 8, 11-23% of people treated with oral semaglutide experienced nausea, compared to 7% of people treated with placebo. The proportion of people who discontinued treatment due to adverse events was 7-14% for people treated with oral semaglutide compared to 3% with placebo.

"For people with type 2 diabetes and requiring insulin treatment, it can be challenging to reach optimal blood sugar control levels due to weight gain and risk of hypoglycaemia," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "In PIONEER 8, oral semaglutide was able to improve blood sugar control for people with a long duration of diabetes and already treated with insulin, with the benefit of clinically meaningful weight reduction, and without increasing the risk of hypoglycaemia."

About PIONEER 8 and the PIONEER clinical trial programme

PIONEER 8 was a 52-week, randomised, double-blinded, placebo-controlled, parallel-group, multicentre, multinational trial with four arms comparing the efficacy and safety of 3, 7 and 14 mg oral semaglutide with placebo in people with type 2 diabetes treated with basal insulin alone or basal/bolus insulin in any combination or premix insulin including combinations of soluble insulins. The insulin treatment could be combined with metformin. The 52-week randomised treatment period was split into two; an initial 26-week period during which the insulin dose was capped at pre-randomisation levels, followed by a 26-week period where insulin treatment was adjusted without any restrictions. PIONEER 8 randomised 731 people with an average of duration of diabetes of 15 years in a 1:1:1:1 manner to receive either a dose of oral semaglutide 3, 7 and 14 mg or placebo in addition to insulin. The primary endpoint and confirmatory secondary endpoints were change from baseline to week 26 in HbA1c and body weight. Key secondary endpoints included change in HbA1c and bodyweight from baseline to week 52.

The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018.

Further information

Media:

 

 

Katrine Sperling +45 3079 6718

krsp@novonordisk.com

Ken Inchausti (US) +1 609 786 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 
Peter Hugreffe Ankersen +45 3075 9085

phak@novonordisk.com

Anders Mikkelsen +45 3079 4461

armk@novonordisk.com

Valdemar Borum Svarrer +45 3079 0301

jvls@novonordisk.com

                

Company announcement No 81 / 2018 


[1]

Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)).

[2]

Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.

PR261018_PIONEER_8_UK


This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Globenewswire

Relateret indhold
12:42 - 
Novo og Teva indgår milliardforlig i patentstrid
11:42 - 
Middag: Jyske, Sydbank og Danske får rygstød af bryllup..
15 mar - 
Fredagens aktier: Femte dag med C25-plus - ISS, Pandora..
Relateret debat
12:24 - 
Så er der lidt fakta om kopi af Victoza, og som v..
16 mar - 
Man kan sige, at hvis teknologien kan levere insulin - ..
16 mar - 
Ja, men det er værd at være obs på - ..
Vedhæftet fil: PR261018_PIONEER_8_UK.pdf
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 mar
NOVO-B
Novo er nu tæt på et pas på område for de kortsigetede. Så jeg vil være OBS på, om købssignalerne æn..
11
15 mar
NOVO-B
Risiko efter store stigning på et godt grundlag kan være at selve grundlaget overhales af noget, der..
4
12:24
NOVO-B
Så er der lidt fakta om kopi af Victoza, og som ventet var patenterne størke nok til at udskyde til ..
2
14 mar
NOVO-B
Den har næste targetområde 352-355 med venteområder i 337, 342 og 348 ;)   https://invst.ly/aa4ld
2
13 mar
NOVO-B
Endnu en gang bevist, at Tresiba nedsætter risiko for Hypoglykæmi (rescuepen) signifikant ift. andre..
2
12 mar
NOVO-B
Enig Alpe. Jeg synes også, at den ser lidt farlig ud pt. Den brød kortvarigt over de to markante top..
2
14 mar
NOVO-B
Dobbelttop 333,20 nu brudt og backtestet, så er OBS på om signaler stadig er grønne   https://invst...
1
12 mar
NOVO-B
udbytte inden længe - så falder den selvfølgelig
1

USA åbning – Goldman Sachs, Boeing & Walt Disney

18-03-2019 14:51:19
I USA er markederne åbnet svagt positivt DOW JONESDow Jones åbner med en lille stigning på 0,06 pct. De tre mest stigende på Dow Jones fra start:Goldman Sachs oppe 0,63 pct.Visa oppe 0,55 pct.Nike oppe 0,50 pct.De tre mest faldende på Dow Jones fra start:Boeing nede 2,10 pct.Walt Disney nede 1,53 pct.ExxonMobil nede 0,36 pct. S&P500S&P500-indekset åbner med en lille stigning på 0,17 pct. De tre me..

Novo og Teva indgår milliardforlig i patentstrid

18-03-2019 12:42:38
Novo Nordisk har indgået forlig med Teva Pharmaceuticals i en patentsag om den storsælgende GLP-1-analog Victoza, som Teva har udfordret patentet på.Aftalen betyder, at Teva kan lancere en generisk version (kopiversion) af Victoza tidligst den 22. december 2023.Det fremgår af en meddelelse fra Novo Nordisk mandag middag.Under visse særlige omstændigheder er der dog også mulighed for, at Tevas vers..

Ambu-produkt sparer omkostninger på amerikanske hospitaler

18-03-2019 11:42:11
Et nyt amerikansk studie viser, at engangsbronkoskoper til kikkertundersøgelser af luftvejene er billigere i brug end genanvendelige skoper.Det skriver Ambu, der selv sælger engangsløsninger til amerikanske hospitaler, i en pressemeddelelse.Ifølge Ambu viser studiet, at ekstraomkostningerne ved brug af et genanvendeligt bronkoskop er på 150 dollar i gennemsnit på de hospitaler, der indgik i studie..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Danske Bank i fokus i ventet grøn start
2
Novo og Teva indgår milliardforlig i patentstrid
3
Ugens regnskaber og nøgletal – Rentemøde, Porsche og olie-lagre
4
Middag: Jyske, Sydbank og Danske får rygstød af bryllupsklokker
5
Amerikansk rentemøde kan give markedet et skub op

Relaterede aktiekurser

Novo Nordisk B A/S 338,20 1,0% Stigning i aktiekurs
Novo Nordisk 50,86 0,7% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. marts 2019 14:55:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20190215.1 - EUROWEB6 - 2019-03-18 14:55:26 - 2019-03-18 14:55:26 - 1 - Website: OKAY